SOLICITATION NOTICE
66 -- Reagent Kits for the Sequencing of Fecal Microbiots
- Notice Date
- 8/14/2013
- Notice Type
- Presolicitation
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- NCI-130116-HN
- Archive Date
- 8/29/2013
- Point of Contact
- Huy Nguyen, Phone: 2402765570, Seena Ninan, Phone: 240-276-5419
- E-Mail Address
-
anh-huy.nguyen@nih.gov, ninans@mail.nih.gov
(anh-huy.nguyen@nih.gov, ninans@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive Room 1E154 Bethesda, MD 20892 Description: The National Cancer Institute (NCI), Division of Cancer Epidemiology & Genetics (DCEG) plans to procure on a sole source basis with Illumina Inc, reagent kits required to support the Nutritional Epidemiology Branch's (NEB) research of Fecal Metagenome & Colorectal Cancer risk The products herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1(b)(2). The North American Industry Classification System code is 325413 and the small business standard is 500 employees. Only one (1) award will be made as a result of this solicitation. This will be awarded as a Firm Fixed Price (FFP) type contract. It has been determined there are no opportunities to acquire green products or services for this procurement. The NEB conducts intramural research in areas related to nutrition, metabolism and cancer which are aimed at lowering human cancer risk. Focus areas of the NEB's research include cancers of the lower gastrointestinal tract. An earlier analyses of 16S analysis found that elevated colorectal cancer risk with higher relative abundance of Fusobacteria and lower relative abundances of Clostridia and Actinobacteria. The reagent kits required will be used to sequence fecal microbiots so that metagenomic analyses can be conducted to validate and deepen sequence so that we can identify bacteria at the level of species. For this research, the NEB is collaborating with the European Molecular Biology Laboratory (EMBL) located in Germany. The EMBL will perform the sequencing and conduct analyses on the colorectal cancer samples provided by the NEB. The EMBL has a Material Transfer Agreement (MTA) with the NEB and has clearance from the National Institute of Health's Office of Human Subjects Research to perform the required research. The EMBL has sequenced fecal samples and bacterial genes of colorectal patients from Europe using Illumina brand reagents kits. Using the same method, the EMBL will sequence samples from the NEB's study of colorectal cancer. In order to conduct a pooling analysis, the NEB will combine the data with the EMBL's colorectal cancer analyses to increase the sample size for the colorectal cancer case-control study. Large numbers of cases and controls are needed for these types of analyses. Results from different laboratories cannot be pooled, due to the difference in results of the analytical artifacts. If the same sequencing method and reagent kits are not used, then the NEB cannot combine the results of the two studies for analysis. Contractor Requirements: •Five (5) Illumina TruSeq SR Cluster Kits v3 -cBot - HS (GD-401-3001) •Five (5) Illumina TruSeq SBS Kits v3 - HS (200-cycles) (FC-401-3001) Delivery: •Within one (1) month from the date of award. •Deliver to the EMBL, Meyerhofstr.1, 60912 Heidelberg, Germany This is not a solicitation for competitive quotations. However, if any interested party, particularly small businesses, believe they can meet the above requirement, they may submit a statement of capabilities via fax or email. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. The capability statement must be received in the NCI contracting office on or before 11:00 AM EST on August 28, 2013. All questions must be in writing and can be faxed (240)-276-5401 or emailed to Anh-Huy Nguyen, Contract Specialist at anh-huy.nguyen@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the System for Award Management (SAM) www.sam.gov. No collect calls will be accepted. Please reference solicitation number NCI-130116-HN on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-130116-HN/listing.html)
- Record
- SN03148281-W 20130816/130814234944-e8c8730857d6cf07ab6ac5a03be998fa (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |